Braze, Inc. (NASDAQ: BRZE) reported better-than-expected sales results for its third quarter and issued strong forecast for FY23.
Braze posted quarterly loss of $0.15 per share, on sales of $93.10 million.
ABM INDUSTRIES INCORPORATED AND SUBSIDIARIES
2023 GUIDANCE
Year Ending October 31, 2023
Reconciliation of Estimated Net Income per Diluted Share to Estimated Adjusted Net Income per Diluted
At its Investor and Analyst Day event, Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) provided an overview of Ligand's corporate structure and business following the successful spin-off of its OmniAb antibody discovery business.